IQVIA Holdings Inc. ($IQV) Stock Forecast: Up 7.5% Today

What is IQVIA Holdings Inc.?

IQVIA Holdings Inc. (IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the healthcare industry. The company's stock had a strong bullish movement today amidst positive sentiment in the diagnostics and research sector.

Why is IQVIA Holdings Inc. going up?

IQV stock is up 7.5% on May 28, 2026 17:36

• IQVIA Holdings Inc. experienced a significant 5.7% surge in its stock price, outperforming its competitors and the broader market, indicating strong investor interest in the company.
• The bullish movement was part of a sector-wide rally in the diagnostics and research industry, with peers like Agilent Technologies and Thermo Fisher Scientific also posting notable gains.
• Analysts' bullish sentiments and positive outlook on IQVIA Holdings, citing factors such as expected revenue and earnings growth, a robust backlog, and strong demand driven by AI adoption, likely contributed to the stock's upward momentum.
• Investors should continue to monitor the sustainability of this rally and any further announcements from leading companies in the sector that could impact IQV's performance.

IQV Price Chart

IQV Technical Analysis

IQV News

IQVIA Holdings Jumps 5.7% Amid Sector-Wide Rally

IQVIA Holdings Inc. saw its stock surge by 5.7% to $175.00, driven by a broad sector-wide rally in the diagnostics and research industry. This movement, which saw several peers like Agilent Technologies and Thermo Fisher Scientific also post significant gains, indicates a shift in investor sentiment towards the entire sector rather than specific company news. Investors are advised to monitor whether this rally is sustainable and if any announcements from leading companies will provide further clarity.

https://news.alphastreet.com/iqvia-holdings-jumps-5-7-amid-sector-wide-rally/amp/

IQVIA Holdings Inc. stock outperforms competitors on strong trading day

IQVIA Holdings Inc. (IQV) stock advanced 2.23% to $165.62, outperforming its competitors and the broader market on a strong trading day. This rise ended a four-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average also saw modest gains during the session.

https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-8a20638e-bb3f8c2ff048

Here's Why Investors Must Hold IQV Stock in Their Portfolios for Now

IQVIA Holdings Inc. (IQV) shares have outperformed the industry, with revenues and earnings expected to grow significantly in 2026 and 2027. The company boasts a record backlog of $34.2 billion, strong demand driven by AI adoption, and an active share repurchase program. However, investors should be aware of its weak liquidity profile and lack of dividend payments.

https://www.tradingview.com/news/zacks:2183212bb094b:0-here-s-why-investors-must-hold-iqv-stock-in-their-portfolios-for-now/

Analysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH)

Two analysts from Truist Financial have issued bullish sentiments on healthcare stocks IQVIA Holdings (IQV) and Lantheus (LNTH). Jailendra Singh maintained a Buy rating on IQVIA Holdings with a price target suggesting a 28.0% upside, while Richard Newitter kept a Buy rating on Lantheus, indicating a 7.6% upside. Both companies show a Strong Buy consensus among analysts.

https://www.theglobeandmail.com/investing/markets/stocks/IQV-N/pressreleases/2150808/analysts-are-bullish-on-top-healthcare-stocks-iqvia-holdings-iqv-lantheus-lnth/

Analysts Are Bullish on Top Healthcare Stocks: IQVIA Holdings (IQV), Lantheus (LNTH)

Analysts are expressing bullish sentiments on healthcare stocks IQVIA Holdings (IQV) and Lantheus (LNTH). Truist Financial analysts maintained Buy ratings for both companies, with IQVIA Holdings having an average price target indicating a 28.0% upside and Lantheus showing a 7.6% upside from current levels, according to analyst consensus.

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2150808/analysts-are-bullish-on-top-healthcare-stocks-iqvia-holdings-iqv-lantheus-lnth/

Trending Today

Prime Medicine ($PRME) Stock Forecast: Up 6.5% Today

Hewlett Packard Enterprise Company ($HPE) Stock Forecast: Up 13.1% Today

Ford Motor Company ($F) Stock Forecast: Up 5.3% Today

Broadcom Inc. ($AVGO) Stock Forecast: Up 5.0% Today

Microsoft Corporation ($MSFT) Stock Forecast: Up 5.3% Today

Kimberly-Clark Corporation ($KMB) Stock Forecast: Down 2.8% Today

Palo Alto Networks Inc. ($PANW) Stock Forecast: Up 9.4% Today

Clorox Company (The) ($CLX) Stock Forecast: Down 5.6% Today

Crowdstrike Holdings Inc. ($CRWD) Stock Forecast: Up 8.5% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.3% Today

IQVIA Holdings Inc. Price History

26.01.2026 - IQV Stock was up 5.2%

• Today's positive movement for IQVIA is linked to its acquisition of drug discovery assets from Charles River Laboratories, enhancing its early-stage research offerings and drug discovery platform.
• The rally was also supported by improved investor sentiment on biotech funding and clinical activity, positioning IQVIA as a resilient business with growth opportunities.
• Despite some concerns about fundamental aspects like revenue growth and free cash flow margin, the market is optimistic about IQVIA's strong 2025 performance projections, including revenue and EPS growth, and collaborations in AI-driven research.
• Overall, IQVIA's bullish momentum reflects investor confidence in its acquisitions, financial performance, and growth potential in healthcare and biotech sectors.

13.01.2026 - IQV Stock was up 5.0%

• Despite concerns about margin compression, IQVIA's Q4 earnings call exceeded revenue expectations, leading to a positive market reaction.
• Analysts remain optimistic about IQVIA's future performance, with recent insider buying and a "Moderate Buy" rating indicating confidence in the company's growth potential.
• The company's focus on AI integration, strategic acquisitions, and addressing macroeconomic challenges demonstrates its commitment to long-term success, driving the bullish movement in its stock price today.

12.01.2026 - IQV Stock was down 8.3%

• Despite strong Q3 earnings and positive FY2026 guidance, IQVIA Holdings' stock dropped by 26% post-financial results, indicating investor concerns.
• The discrepancy between the company's 11% annual EPS growth and the 22% decline in share price over a three-year period suggests potential misvaluation or underlying issues impacting investor sentiment.
• The recent acquisition of a significant number of IQVIA shares by Eubel Brady & Suttman Asset Management Inc. may indicate confidence in the company's long-term prospects, though market sentiment remains cautious.
• The overall bearish trend in IQV's stock could be linked to broader challenges in the medical research sector, illustrated by negative trends in competitors such as ICON plc and Charles River Laboratories International, influencing investor sentiment industry-wide.

06.03.2026 - IQV Stock was up 0.2%

• IQVIA Holdings Inc. (IQV) stock price saw a significant increase following the launch of the IQVIA.ai unified agentic AI platform in collaboration with Nvidia, aimed at enhancing operational efficiency and decision-making in the life sciences industry.
• The "Buy" rating upgrade from TD Cowen and the positive reception of the platform by top pharmaceutical companies contributed to investor optimism and drove the bullish movement in IQV's stock price.
• Aberdeen Group plc's substantial increase in stake in IQVIA Holdings Inc. and the company's strong Q4 earnings performance with exceeded EPS expectations and year-over-year revenue growth further bolstered investor confidence in IQV's future prospects.

27.01.2026 - IQV Stock was up 5.2%

• Primecap Management Co. CA reduced its stake in IQVIA Holdings Inc., but other institutional investors increased their holdings, indicating varying sentiments among investors.
• The acquisition of drug discovery assets from Charles River Laboratories is seen as a strategic move to expand IQVIA's capabilities and enhance its early-stage research offerings, potentially boosting investor confidence.
• Analysts adjusting price targets for IQV post-earnings report and re-segmentation suggest a positive outlook for the company, with some considering it a strong buy despite potential competition from AI stocks.
• Broyhill Asset Management's endorsement of IQV as a top contributor to its portfolio highlights the company's strong performance and its resilience in the face of concerns over biotech funding and clinical activity, positioning it favorably in the market.

23.03.2026 - IQV Stock was down 9.0%

• The bearish movement in IQV's stock today could be attributed to profit-taking by investors after a period of sustained growth.
• The positive news surrounding Royalty Pharma's dividend approval and partnership with Johnson & Johnson may have diverted some investor attention away from IQVIA Holdings Inc.
• The initiation of coverage by BMO Capital with an Outperform rating might have raised expectations for IQV's stock, leading to a sell-off as investors locked in profits.
• The Google Discover Core Update emphasizing personalized news feeds on IQVIA Holdings Inc. could have triggered algorithmic trading or increased volatility in the stock as investors digested the implications of the update.

05.04.2026 - IQV Stock was up 10.0%

• IQVIA reported strong first-quarter 2026 financial results, with revenue increasing by 8.4% year-over-year to $4,151 million and Adjusted Diluted Earnings per Share up by 7.4%. This positive performance was driven by strong results in both Commercial Solutions and Research & Development Solutions.
• Despite exceeding earnings and revenue forecasts, the stock initially dipped in pre-market trading due to investor concerns. This could be attributed to market volatility and increased competition in the industry.
• IQVIA's strong performance was fueled by AI solutions, new drug launches, and strategic partnerships, along with aggressive share repurchases. The company's focus on innovation and growth strategies seems to be resonating well with investors, leading to a bullish market movement for the stock.

05.04.2026 - IQV Stock was up 5.2%

• IQVIA reported strong first-quarter 2026 financial results, exceeding revenue and earnings expectations, driven by robust performance in Commercial Solutions and Research & Development Solutions.
• Despite beating forecasts and reaffirming its full-year guidance, IQV's stock initially dipped in pre-market trading due to investor concerns, possibly related to market volatility and competition worries.
• The market movement turned bullish as investors likely recognized the company's strong fundamentals, including its AI solutions, new drug launches, and strategic partnerships, leading to a positive outlook for continued growth.
• Integration of AI in life sciences operations, as highlighted in industry reports, could have also positively influenced investor sentiment towards IQVIA, showcasing the company's innovative approach and potential for further advancements in the sector.

06.04.2026 - IQV Stock was up 11.2%

• IQVIA reported strong Q1 2026 financial results, with revenue reaching $4.15 billion, an 8.4% increase year-over-year, and EPS of $1.61, beating estimates.
• The stock surged by 9.60% on May 5, driven by the company's robust performance across its segments and exceeding earnings and revenue expectations.
• Analysts maintain a positive outlook on IQV, citing AI as a key driver for its success, despite some technical sell signals and debt concerns.
• The market responded positively to IQV's strong trading day, outperforming competitors and reflecting overall bullish sentiment towards the stock.

28.04.2026 - IQV Stock was up 7.5%

• IQVIA Holdings Inc. experienced a significant 5.7% surge in its stock price, outperforming its competitors and the broader market, indicating strong investor interest in the company.
• The bullish movement was part of a sector-wide rally in the diagnostics and research industry, with peers like Agilent Technologies and Thermo Fisher Scientific also posting notable gains.
• Analysts' bullish sentiments and positive outlook on IQVIA Holdings, citing factors such as expected revenue and earnings growth, a robust backlog, and strong demand driven by AI adoption, likely contributed to the stock's upward momentum.
• Investors should continue to monitor the sustainability of this rally and any further announcements from leading companies in the sector that could impact IQV's performance.

28.04.2026 - IQV Stock was up 5.5%

• IQVIA Holdings Inc. (IQV) stock outperformed its competitors and the broader market, breaking a four-day losing streak, fueled by strong trading activity.
• Analysts' bullish sentiments and optimistic price targets for IQV indicate confidence in the company's growth prospects, driven by factors such as strong demand from AI adoption and an active share repurchase program.
• The positive outlook for IQVIA Holdings Inc. (IQV) reflects investors' confidence in the company's revenue and earnings growth potential in the coming years, despite concerns about its weak liquidity profile and lack of dividend payments.

20.04.2026 - IQV Stock was down 5.7%

• The bearish movement in IQV's stock could be linked to CFRA downgrading its rating on the shares from Buy to Hold, potentially creating investor uncertainty and selling pressure.
• Despite IQVIA's strong Q1 earnings showing data strength and AI ambitions, the market reaction might have been influenced by the moderation in the stock rating, causing a shift in investor sentiment.
• The announcement of Labcorp's new AI-powered app for lab results interpretation could have negatively impacted IQV's stock, as investors may perceive increased competition or technological advancements in the healthcare data analytics field.
• IQVIA's decision to significantly increase its share repurchase program signals confidence in its financial health and future growth prospects, but the market might be reacting cautiously to this move amidst broader market uncertainties and the recent rating downgrade.